Document ID: chunk:federal_register_of_legislation:F2023L00016:reg:9:p7
Version: federal_register_of_legislation:F2023L00016
Segment Type: reg
Provision Reference: reg 9 (pt 7/8)
Character Range: 21864–24899

atrial flutter;
Note: sepsis is defined in the Schedule 1 – Dictionary.
(74)      having infiltration of the myocardium due to:
(a)          amyloidosis;
(b)          haemochromatosis; or
(c)          sarcoidosis;
at the time of the clinical worsening of atrial fibrillation or atrial flutter;
(75)      having an autoimmune or inflammatory disease from the specified list of autoimmune or inflammatory diseases at the time of the clinical worsening of atrial fibrillation or atrial flutter;
Note: specified list of autoimmune or inflammatory diseases is defined in the Schedule 1 - Dictionary.
(76)      being overweight or obese for at least the 5 years before the clinical worsening of atrial fibrillation or atrial flutter;
Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
(77)      having obstructive sleep apnoea at the time of  the clinical worsening of atrial fibrillation or atrial flutter;
(78)      having smoked tobacco products in an amount of at least 5 pack-years before the clinical worsening of atrial fibrillation or atrial flutter; and if smoking has ceased before the clinical worsening of atrial fibrillation or atrial flutter, then that worsening occurred within 5 years of cessation;
Note: one pack-year is defined in the Schedule 1 - Dictionary.
(79)      having gastro-oesophageal reflux disease at the time of the clinical worsening of atrial fibrillation or atrial flutter;
(80)      having chronic renal failure at the time of the clinical worsening of atrial fibrillation or atrial flutter;
Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
(81)      having systemic chemotherapy for a malignant disease at the time of the clinical worsening of atrial fibrillation or atrial flutter;
Note: Examples of systemic chemotherapy for malignant disease include:
(a) anthracyclines including doxorubicin;
(b) HER2 inhibitors including trastuzumab; and
(c) tyrosine kinase inhibitors including ibrutinib.
(82)      having glucocorticoid therapy as specified before the clinical worsening of atrial fibrillation or atrial flutter, and if the glucocorticoid therapy as specified has ceased or decreased before the clinical worsening of atrial fibrillation or atrial flutter, then that worsening occurred within 30 days of cessation of therapy;
Note: glucocorticoid therapy as specified is defined in the Schedule 1 - Dictionary.
(83)      taking a non-topical, non-steroidal, anti-inflammatory drug, excluding low-dose aspirin, for a continuous period at least 30 days within the 60 days before the clinical worsening of atrial fibrillation or atrial flutter;
Note: low-dose aspirin is defined in the Schedule 1 – Dictionary.
(84)      taking a drug from the specified list of drugs within the 7 days before the clinical worsening of atrial fibrillation or atrial flutter.
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(85)      taking a bisphosphonate: for a continuous period at least 30 days within the 60 days before the clinical worsening